PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-4.70
Negative P/E while Healthcare median is -2.17. Seth Klarman would scrutinize path to profitability versus peers.
No Data
No Data available this quarter, please select a different quarter.
-23.32
Negative equity while Healthcare median P/B is 2.62. Seth Klarman would investigate balance sheet restructuring potential.
-126.01
Negative FCF while Healthcare median P/FCF is -14.60. Seth Klarman would investigate cash flow improvement potential.
-126.09
Negative operating cash flow while Healthcare median P/OCF is -5.71. Seth Klarman would investigate operational improvement potential.
-23.32
Negative fair value while Healthcare median is 2.61. Seth Klarman would investigate valuation model issues.
-5.32%
Negative earnings while Healthcare median yield is -0.20%. Seth Klarman would investigate path to profitability.
-0.79%
Negative FCF while Healthcare median yield is -0.23%. Seth Klarman would investigate cash flow improvement potential.